Novavax Inc
(XSWX:NVAX)
CHF
7.61
-0.14 (-1.78%)
Market Cap: 1.24 Bil
Enterprise Value: 843.42 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 50/100 Novavax Inc at H C Wainwright Global Investment Conference (Virtual)- Pre-Recorded Transcript
Sep 13, 2021 / 11:00AM GMT
Vernon Tolentino Bernardino
H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst
Good day, everyone, and thank you for joining the H.C. Wainwright 23rd Annual Global Investment Conference. My name is Vernon Bernardino, and I'm a senior analyst at H.C. Wainwright. While we are in a virtual format this year, we're confident we can provide value to you with over 850 companies presenting and available for one-on-one meetings. We recommend you meet with all of our companies as each has a special story that you should hear.
With that said, I'd like to introduce to -- you to a special company, a company called Novavax, which is developing next-generation vaccines. With us today are President of R&D, Greg Glenn; and Chief Commercial Officer/Chief Business Officer, John Trizzino. Welcome, gentlemen.
John Joseph Trizzino;Gregory M. Glenn
Novavax, Inc. - Executive VP and Chief Business & Commercial Officer;Novavax, Inc. - President of Research &
Thank you.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot